VioQuest Pharmaceuticals, Inc. (VOQP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2007 | 9.74 Million USD | 84.47% |
| 2006 | 5.28 Million USD | -59.73% |
| 2005 | 13.11 Million USD | 222.85% |
| 2004 | 4.06 Million USD | 100.13% |
| 2003 | 2.02 Million USD | 1203.02% |
| 2002 | 155.75 Thousand USD | -19.3% |
| 2001 | 193.01 Thousand USD | 15.41% |
| 2000 | 167.24 Thousand USD | 268.41% |
| 1999 | 45.39 Thousand USD | 1813.87% |
| 1998 | 2372.00 USD | -96.47% |
| 1997 | 67.14 Thousand USD | 514.57% |
| 1996 | 10.92 Thousand USD | 0.4% |
| 1995 | 10.88 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2008 Q1 | 1.66 Million USD | -36.85% |
| 2008 Q2 | 1.02 Million USD | -38.45% |
| 2007 Q4 | 2.64 Million USD | -1.1% |
| 2007 FY | 9.74 Million USD | 84.47% |
| 2007 Q3 | 2.67 Million USD | 24.72% |
| 2007 Q2 | 2.14 Million USD | -6.1% |
| 2007 Q1 | 2.28 Million USD | 14.14% |
| 2006 Q1 | 1.9 Million USD | -78.87% |
| 2006 FY | 5.28 Million USD | -59.73% |
| 2006 Q4 | 1.99 Million USD | 111.07% |
| 2006 Q3 | 947.37 Thousand USD | -47.96% |
| 2006 Q2 | 1.82 Million USD | -4.63% |
| 2005 Q3 | 1.62 Million USD | 40.6% |
| 2005 FY | 13.11 Million USD | 222.85% |
| 2005 Q2 | 1.15 Million USD | -11.69% |
| 2005 Q1 | 1.3 Million USD | 89.57% |
| 2005 Q4 | 9.03 Million USD | 457.75% |
| 2004 Q1 | 745.79 Thousand USD | 31.18% |
| 2004 FY | 4.06 Million USD | 100.13% |
| 2004 Q4 | 688.34 Thousand USD | -14.18% |
| 2004 Q3 | 802.07 Thousand USD | -37.96% |
| 2004 Q2 | 1.29 Million USD | 73.35% |
| 2003 FY | 2.02 Million USD | 1203.02% |
| 2003 Q1 | 341.24 Thousand USD | 791.15% |
| 2003 Q3 | 550.88 Thousand USD | -3.17% |
| 2003 Q2 | 568.91 Thousand USD | 66.72% |
| 2003 Q4 | 568.52 Thousand USD | 3.2% |
| 2002 Q2 | 52.52 Thousand USD | 26.78% |
| 2002 FY | 155.75 Thousand USD | -19.3% |
| 2002 Q4 | 38.29 Thousand USD | 62.9% |
| 2002 Q3 | 23.5 Thousand USD | -55.25% |
| 2002 Q1 | 41.43 Thousand USD | -47.99% |
| 2001 Q2 | 32.23 Thousand USD | -31.2% |
| 2001 Q1 | 46.84 Thousand USD | -2.81% |
| 2001 Q4 | 79.67 Thousand USD | 132.51% |
| 2001 FY | 193.01 Thousand USD | 15.41% |
| 2001 Q3 | 34.26 Thousand USD | 6.31% |
| 2000 Q4 | 48.2 Thousand USD | -26.47% |
| 2000 Q3 | 65.55 Thousand USD | 270.78% |
| 2000 Q2 | 17.68 Thousand USD | -50.62% |
| 2000 Q1 | 35.8 Thousand USD | 0.0% |
| 2000 FY | 167.24 Thousand USD | 268.41% |
| 1999 FY | 45.39 Thousand USD | 1813.87% |
| 1998 FY | 2372.00 USD | -96.47% |
| 1997 FY | 67.14 Thousand USD | 514.57% |
| 1996 FY | 10.92 Thousand USD | 0.4% |
| 1995 FY | 10.88 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HST Global, Inc. | -140.9 Thousand USD | 7014.106% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 1518.22% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | 5780.418% |
| CytoDyn Inc. | -18.05 Million USD | 153.951% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 116.515% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| MultiCell Technologies, Inc. | -722.81 USD | 1347958.912% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | 636.385% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 293.131% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | 32626.906% |
| Reve Technologies, Inc. | -181.48 Thousand USD | 5468.19% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | -9.7 Million USD | 200.38% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 117.551% |
| SQZ Biotechnologies Company | -75.82 Million USD | 112.849% |
| Resverlogix Corp. | -12.74 Million USD | 176.417% |
| Neon Bloom, Inc. | -389.57 Thousand USD | 2600.824% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 496.79% |
| Mesoblast Limited | -84.14 Million USD | 111.578% |
| GB Sciences, Inc. | -1.42 Million USD | 785.843% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | 1518.22% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 154.589% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 386.124% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 246.547% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 407.501% |
| ContraFect Corporation | -56.88 Million USD | 117.125% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 454.163% |
| BioStem Technologies, Inc. | -7.77 Million USD | 225.241% |
| LadRx Corporation | -3.82 Million USD | 354.796% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 161.39% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | 970.64% |
| CSL Limited | 3.7 Billion USD | 99.737% |
| Biomind Labs Inc. | -1 Million USD | 1064.979% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | 1146.024% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 88.097% |
| Nascent Biotech, Inc. | -2.22 Million USD | 536.905% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 113.572% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -98.227% |
| GeneThera, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | -175.211% |
| Adynxx, Inc. | - USD | -Infinity% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 734.254% |
| Marizyme, Inc. | -34.08 Million USD | 128.582% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 216.676% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | 1825.175% |
| Zenith Capital Corp. | -8.94 Million USD | 208.939% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 441.78% |
| Halberd Corporation | -75.05 Thousand USD | 13081.291% |
| Genus plc | 6.4 Million USD | -52.226% |
| Pharming Group N.V. | -4.87 Million USD | 299.659% |
| MetaStat, Inc. | - USD | -Infinity% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 590.439% |
| IMV Inc. | -38.67 Million USD | 125.193% |
| Affymax, Inc. | -15.04 Million USD | 164.751% |
| SYBLEU INC | -149.18 Thousand USD | 6630.674% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | 1033.186% |
| Enzolytics Inc. | -2.14 Million USD | 553.391% |
| argenx SE | -425.04 Million USD | 102.292% |
| AVAX Technologies, Inc. | 6.69 Million USD | -45.565% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 794.902% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 829.537% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | -3.74 Million USD | 360.047% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | 38806.631% |
| Cell Source, Inc. | -4.32 Million USD | 325.241% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | 2116.813% |
| Q BioMed Inc. | -3.44 Million USD | 382.749% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 329.861% |
| Capstone Therapeutics Corp. | -1.25 Million USD | 875.673% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 470.785% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 313.898% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 117.722% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 435.802% |
| Rebus Holdings, Inc. | -664 Thousand USD | 1567.238% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | 1090.034% |
| Skye Bioscience, Inc. | -13.67 Million USD | 171.26% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | 622.56% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 585.967% |
| ONE Bio Corp. | 13.68 Million USD | 28.791% |
| Curative Biotechnology, Inc. | -1.93 Million USD | 604.109% |
| Wesana Health Holdings Inc. | -1.12 Million USD | 966.069% |
| Agentix Corp. | -1.37 Million USD | 810.218% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 433.709% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | 716.863% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | 56023.65% |
| Kadimastem Ltd | -3.04 Million USD | 420.449% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | 3822.389% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 2444.874% |
| NovAccess Global Inc. | -2.46 Million USD | 494.95% |
| Itoco Inc. | -919.14 Thousand USD | 1159.954% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | 4526.821% |
| Qrons Inc. | -643.67 Thousand USD | 1613.563% |
| Mobile Lads Corp. | -554.55 Thousand USD | 1856.822% |
| Genscript Biotech Corporation | -415.79 Million USD | 102.343% |
| International Stem Cell Corporation | -663 Thousand USD | 1569.451% |
| Bioxytran, Inc. | -3.82 Million USD | 355.028% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | 18607.711% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | 47998.029% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 126.864% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | 702.13% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -735.83 Thousand USD | 1424.0% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 413.162% |
| Neutra Corp. | -229.48 Thousand USD | 4345.339% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 155.547% |
| PureTech Health plc | -146.19 Million USD | 106.664% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 145.332% |
| IXICO plc | -1.43 Million USD | 777.972% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 202.649% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 107.998% |
| CSL Limited | 3.81 Billion USD | 99.744% |
| Cellectis S.A. | -108.85 Million USD | 108.95% |